Skip to main content
Top
Published in: International Urology and Nephrology 3/2011

Open Access 01-09-2011 | Urology – Original Paper

Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature

Authors: Chi Yuen Cheung, Man Fai Lam, King Chung Lee, Gavin Sheung Wai Chan, Kwok Wah Chan, Ka Foon Chau, Chun Sang Li, Tak Mao Chan, Kar Neng Lai

Published in: International Urology and Nephrology | Issue 3/2011

Login to get access

Abstract

Objectives

To present and discuss the epidemiological and clinical aspects, as well as therapeutic options and outcome of de novo renal cell carcinoma (RCC) of the native kidneys in a series of Chinese renal transplant recipients.

Patients and Methods

A retrospective, cohort study examining all renal transplant recipients with the diagnosis of RCC of native kidney followed up in two major regional hospitals in Hong Kong between January 2000 and December 2009. Clinical data included age, gender, cause of renal failure, symptoms at presentation, duration of transplantation, immunosuppressive therapy, and history of acquired cystic kidney disease (ACKD). Laboratory, radiographic, operative, and pathology reports were used to assess the tumor extent.

Results

Among the 1,003 renal transplant recipients recruited, 12 transplant recipients had a nephrectomy for a total of 13 RCC. The prevalence of de novo RCC was 1.3%. The mean age at diagnosis of RCC was 48.4 years, and the median time from transplantation to diagnosis was 6.1 years. ACKD was found in 6 (50%) of the patients. All patients except one were asymptomatic. pT1 disease was found in ten patients with a mean tumor size of 3.2 cm. All patients were treated successfully with radical nephrectomy. After a median follow-up of 38 months, two patients (16.7%) died. One died of sepsis, and the other died of metastatic carcinoma.

Conclusions

With increasing data showing a better prognosis if RCC is detected early by screening, it is time to consider screening all kidney transplant recipients for ACKD and RCC.
Literature
1.
go back to reference Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transpl 4:905–913CrossRef Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transpl 4:905–913CrossRef
2.
go back to reference Penn I (1999) Post-transplantation malignancies. Transpl Proc 31:1260–1262CrossRef Penn I (1999) Post-transplantation malignancies. Transpl Proc 31:1260–1262CrossRef
3.
go back to reference Doublet J, Peraldi M, Gattegno B, Thibault P, Sraer JD (1997) Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 158:42–44PubMedCrossRef Doublet J, Peraldi M, Gattegno B, Thibault P, Sraer JD (1997) Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 158:42–44PubMedCrossRef
4.
go back to reference American Joint Committee on Cancer (2002) Kidney. AJCC cancer staging manual, 6th edn. New York, Springer, pp 323–325 American Joint Committee on Cancer (2002) Kidney. AJCC cancer staging manual, 6th edn. New York, Springer, pp 323–325
5.
go back to reference Kovacs G, Akhtar M, Beckwith BJ et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133PubMedCrossRef Kovacs G, Akhtar M, Beckwith BJ et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133PubMedCrossRef
6.
go back to reference Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef
7.
go back to reference Sheil A, Flavel S, Disney A, Mathew T (1985) Cancer development in patients progressing to dialysis and renal transplant. Transpl Proc 17:1685–1688 Sheil A, Flavel S, Disney A, Mathew T (1985) Cancer development in patients progressing to dialysis and renal transplant. Transpl Proc 17:1685–1688
8.
go back to reference Schwarz A, Vatandaslar S, Merkel S, Haller H (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2:750–756PubMedCrossRef Schwarz A, Vatandaslar S, Merkel S, Haller H (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2:750–756PubMedCrossRef
9.
go back to reference Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH (1995) Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology 195:667–671PubMed Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH (1995) Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology 195:667–671PubMed
10.
go back to reference Hoshida Y, Nakanishi H, Shin M, Satoh T, Hanai J, Aozasa K (1999) Renal neoplasia in patients receiving dialysis and renal transplantation: clinico-pathological features and p53 gene mutation. Transplantation 68:385–390PubMedCrossRef Hoshida Y, Nakanishi H, Shin M, Satoh T, Hanai J, Aozasa K (1999) Renal neoplasia in patients receiving dialysis and renal transplantation: clinico-pathological features and p53 gene mutation. Transplantation 68:385–390PubMedCrossRef
11.
go back to reference Hughson MD, Buchwald D, Fox M (1986) Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med 110:592–601PubMed Hughson MD, Buchwald D, Fox M (1986) Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med 110:592–601PubMed
12.
go back to reference Goh A, Vathsala A (2011) Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 11:86–92PubMedCrossRef Goh A, Vathsala A (2011) Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 11:86–92PubMedCrossRef
13.
go back to reference Filocamo MT, Zanazzi M, Li Marzi V et al (2009) Renal cell carcinoma of native kidney after renal transplantation: clinical relevance of early detection. Transpl Proc 41:4197–4201CrossRef Filocamo MT, Zanazzi M, Li Marzi V et al (2009) Renal cell carcinoma of native kidney after renal transplantation: clinical relevance of early detection. Transpl Proc 41:4197–4201CrossRef
14.
go back to reference Neuzillet Y, Lay F, Luccioni A et al (2005) De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 103:251–257PubMedCrossRef Neuzillet Y, Lay F, Luccioni A et al (2005) De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 103:251–257PubMedCrossRef
15.
go back to reference Luciani LG, Cestari R, Tallarigo C (2000) Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology 56:58–62PubMedCrossRef Luciani LG, Cestari R, Tallarigo C (2000) Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology 56:58–62PubMedCrossRef
16.
go back to reference Penn I (1995) Primary kidney tumors before and after renal transplantation. Transplantation 59:480–485PubMed Penn I (1995) Primary kidney tumors before and after renal transplantation. Transplantation 59:480–485PubMed
17.
go back to reference Hoshida Y, Tsukuma H, Yasunaga Y et al (1997) Cancer risk after renal transplantation in Japan. Int J Cancer 71:517–520PubMedCrossRef Hoshida Y, Tsukuma H, Yasunaga Y et al (1997) Cancer risk after renal transplantation in Japan. Int J Cancer 71:517–520PubMedCrossRef
18.
go back to reference Ishikawa N, Tanabe K, Tokumoto T et al (1998) Renal cell carcinoma of native kidneys in renal transplant recipients. Transpl Proc 30:3156–3158CrossRef Ishikawa N, Tanabe K, Tokumoto T et al (1998) Renal cell carcinoma of native kidneys in renal transplant recipients. Transpl Proc 30:3156–3158CrossRef
19.
go back to reference Hughson MD, Bigler S, Dickman K, Kovacs G (1999) Renal cell carcinoma of end stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification. Mod Pathol 12:301–309PubMed Hughson MD, Bigler S, Dickman K, Kovacs G (1999) Renal cell carcinoma of end stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification. Mod Pathol 12:301–309PubMed
20.
go back to reference Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182:1271–1279PubMedCrossRef Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182:1271–1279PubMedCrossRef
21.
go back to reference Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135PubMedCrossRef Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135PubMedCrossRef
22.
23.
go back to reference Brugarolas J, Lotan Y, Watumull L, Kabbani W (2008) Sirolimus in metastatic renal cell carcinoma. J Clin Oncol 26:3457–3460PubMedCrossRef Brugarolas J, Lotan Y, Watumull L, Kabbani W (2008) Sirolimus in metastatic renal cell carcinoma. J Clin Oncol 26:3457–3460PubMedCrossRef
24.
go back to reference Hudes G, Carducci M, Tomczak P et al (2007) Global ARCC Trial. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef Hudes G, Carducci M, Tomczak P et al (2007) Global ARCC Trial. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
25.
go back to reference Kasiske BL, Vazquez MA, Harmon WE et al. (2000) The American society of transplantation: recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11(Suppl 15): S1-86 Kasiske BL, Vazquez MA, Harmon WE et al. (2000) The American society of transplantation: recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11(Suppl 15): S1-86
26.
go back to reference Wiesel M, Carl S, Drehmer I, Hofmann WJ, Zeier M, Staehler G (1997) The clinical significance of renal cell carcinoma in dialysis dependent patients in comparison with kidney transplant recipients. Urologe A 36:126–129PubMedCrossRef Wiesel M, Carl S, Drehmer I, Hofmann WJ, Zeier M, Staehler G (1997) The clinical significance of renal cell carcinoma in dialysis dependent patients in comparison with kidney transplant recipients. Urologe A 36:126–129PubMedCrossRef
27.
go back to reference Moudouni SM, Lakmichi A, Tligui M et al (2006) Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int 98:298–302PubMedCrossRef Moudouni SM, Lakmichi A, Tligui M et al (2006) Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int 98:298–302PubMedCrossRef
28.
go back to reference Schmidt R, Stippel D, Krings F, Pollok M (1995) Malignancies of the genito-urinary system following renal transplantation. Br J Urol 75:572–577PubMedCrossRef Schmidt R, Stippel D, Krings F, Pollok M (1995) Malignancies of the genito-urinary system following renal transplantation. Br J Urol 75:572–577PubMedCrossRef
29.
go back to reference Terasawa Y, Suzuki Y, Morita M, Kato M, Suzuki K, Sekino H (1994) Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients. J Urol 152:846–851PubMed Terasawa Y, Suzuki Y, Morita M, Kato M, Suzuki K, Sekino H (1994) Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients. J Urol 152:846–851PubMed
30.
go back to reference Sasagawa I, Terazawa Y, Ishizagi M et al (1992) Comparison of ultrasonography, computerized tomography and angiography in dialysis patients with renal cell carcinoma. Urol Int 49:206–210PubMedCrossRef Sasagawa I, Terazawa Y, Ishizagi M et al (1992) Comparison of ultrasonography, computerized tomography and angiography in dialysis patients with renal cell carcinoma. Urol Int 49:206–210PubMedCrossRef
31.
go back to reference Thompson IM, Peck M (1988) Improvement in survival of patients with renal cell carcinoma: the role of the serendipitously detected tumor. J Urol 140:487–490PubMed Thompson IM, Peck M (1988) Improvement in survival of patients with renal cell carcinoma: the role of the serendipitously detected tumor. J Urol 140:487–490PubMed
32.
go back to reference Ishikawa I, Honda R, Yamada Y, Kakuma T (2004) Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial 8:468–473PubMedCrossRef Ishikawa I, Honda R, Yamada Y, Kakuma T (2004) Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial 8:468–473PubMedCrossRef
Metadata
Title
Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature
Authors
Chi Yuen Cheung
Man Fai Lam
King Chung Lee
Gavin Sheung Wai Chan
Kwok Wah Chan
Ka Foon Chau
Chun Sang Li
Tak Mao Chan
Kar Neng Lai
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2011
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-011-9912-2

Other articles of this Issue 3/2011

International Urology and Nephrology 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine